Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
Want to see JP:2395 full AI Analyst Report?
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,141.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)231.41K
Market Cap
¥50.79B
Enterprise Value¥73.51B
Total Cash (Recent Filing)¥11.57B
Total Debt (Recent Filing)¥36.58B
Price to Earnings (P/E)12.9
Beta0.95
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.79%
Share Statistics
EPS (TTM)121.63
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)1.37
Price to Sales (P/S)1.81
P/FCF Ratio18.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,090.00Price Target Upside28.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)120.35
Revenue Forecast (FY)¥36.61B
Bulls Say, Bears Say
Bulls Say
High MarginsNear-50% gross margin and ~14% net margin provide durable profitability for a specialized service provider. Strong margins create a buffer to absorb project variability, fund specialized facilities and scientific staff, and support reinvestment and shareholder returns even if top-line growth moderates.
Fee-for-service Preclinical ModelA fee-for-service preclinical business supplies predictable, project‑based revenue and repeat engagement potential with pharma/biotech clients. High technical barriers (labs, regulatory know‑how, accredited processes) and secular outsourcing trends support long‑term client stickiness and stable demand.
Positive Operating Cash Flow TrendConsistent positive operating cash flow and improvement in 2026 indicate core operations generate cash. Durable OCF strengthens the company's ability to fund working capital, necessary capex and dividends internally, reducing near‑term reliance on external financing.
Bears Say
Rising LeverageDebt roughly equal to equity increases financial leverage and reduces balance‑sheet flexibility. Higher leverage raises interest costs and magnifies downside risk if margins or revenues deteriorate, constraining the firm's ability to invest or absorb shocks without external funding.
Margin Compression And Revenue SoftnessA 2.5% revenue decline in 2026 alongside material margin compression versus prior years signals weakening demand or utilization. Persistent top‑line softness and squeezed margins limit scale economics, reduce reinvestment capacity, and heighten the need for efficiency improvements to sustain returns.
Volatile Free Cash Flow And Weak Cash ConversionVolatile FCF (negative 2023–2025, positive 2026) and low operating cash flow relative to net income (~21%) point to working‑capital swings or high investment spend. Weak cash conversion limits capacity to delever, sustain dividends or fund expansion without raising external capital.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1141.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥50.79B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 86 days.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Shin Nippon Biomedical Laboratories, Ltd. released its earnings results on May 11, 2026. The company reported ¥55.15 earnings per share for the quarter, beating the consensus estimate of N/A by ¥55.15.
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Undervalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 2.79%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Shin Nippon Biomedical Laboratories, Ltd. reported an EPS of ¥55.15 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -11.498%.
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥2,090.00
▲(28.85% Upside)
Technical Analysis
Options Prices
Currently, No data available
---